Trial reportNutrients2026
The Effects of Multi-Strain Probiotic SLAB51 Intake on Aerobic Performance and Oxidative Stress Responses in Elite Athletes: A Randomized Crossover Trial.
Trial report in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesExercise performance and recovery depend on interactions between energy metabolism and redox regulation. SLAB51, a multi-strain probiotic, may influence oxygen-related metabolism and antioxidant responses, but evidence in elite athletes remains limited. This study aimed to evaluate the effects of SLAB51 supplementation on aerobic exercise capacity and oxidative stress responses in elite athletes.
methodsThis randomized, double-blind, placebo-controlled crossover trial evaluated the effects of SLAB51 supplementation on aerobic exercise performance and oxidative stress in elite athletes. Participants received SLAB51 and placebo for one week each, separated by a two-week washout period. Assessments were performed at baseline, after a single intake, and after one week of intake. Exercise performance was evaluated using a treadmill-based Bruce protocol, and physiological and oxidative stress markers were measured. Data were analyzed using two-way repeated-measures analysis of variance (ANOVA), supplemented by post hoc linear mixed-effects models (LMMs) accounting for the crossover design.
resultsThe original ANOVA showed significant treatment × time interactions for exercise duration, duration above a respiratory exchange ratio (RER) of 1.0, and pre-exercise superoxide dismutase (SOD) activity, but not for maximal oxygen uptake, lactate removal, or malondialdehyde concentration. The additional post hoc LMM analysis also identified a significant treatment difference in exercise duration after one week (mean difference = 33.32 s, 95% CI: 17.42-49.22,
conclusionsThese findings support the potential benefits of one-week SLAB51 supplementation for exercise duration in elite athletes, consistent with the additional crossover-adjusted analysis. Favorable differences in duration above RER 1.0 and pre-exercise antioxidant enzyme activity warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.